Objectives: Cancer patients have to cope with anxieties -concerning their prognosis, potential recurrence/progression, and treatment-associated sequelae. Stress-related psychosocial factors influence survival and disease-related mortality in cancer patients. Despite improvements in diagnosis and treatment, bladder cancer (BC) remains characterized by high rates of recurrence and progression. We screened -pre-therapeutically the stress level of BC patients stratified by gender, disease state, treatment, and other factors by -self-administered validated questionnaires to integrate them into psychosocial support as needed. Methods: A cross-sectional analysis of distress and need of psychosocial care was done in 301 patients undergoing treatment for BC by 2 questionnaires (Distress Thermometer [DT] and Hornheider Screening Instrument). Results: Of the 301 patients, 230 patients underwent transurethral resection for a first -diagnosis, 63 for recurrent disease, 37 had progressive disease, and 25 had advanced metastatic disease and eventually died of BC. The mean stress level in all patients was 4.6. Twenty-eight percent of the patients expressed a need for psychosocial support. In patients with progressive disease, significantly higher stress scores were seen as well as a higher need of psychosocial care (5.4 and 41%). Conclusions: The median DT-level of 4.6 indicates moderate psychosocial stress in BC patients. From a stress level of 5, the recommendations of a psycho-oncological supervision are pronounced, so that our study showed that early systematic evaluation of psychosocial needs in BC patients is important.

Keywords:
Bladder cancer, Distress, Gender, Progression, Psychosocial stress, Recurrence
1.
Robert-Koch-Institut. Bericht zum Krebsgeschehen in Deutschland. http://edoc.rki.de/documents/rki_fv/renGkGzAqwKc2/PDF/28oaKVmif0wDk.pdfAqwKc2/PDF/28oaKVmif0wDk.pdf, 2016.
2.
Robert-Koch-Institut. Zentrum für Krebsregisterdaten. http:// www. krebsdaten. de/Krebs/SiteGlobals/Forms/Datenbankabfrage/datenbankabfrage_stufe1_form.html.
3.
Leitlinienprogramm Onkologie. S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms – Konsultationsfassung. Leitlinienprogramm Onkologie der AWMF, Deutsche Krebsgesellschaft e.V. Deutsche Krebshilfe e.V., 2016.
4.
Babjuk M, Böhle A, Burger M, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017; 71: 447–461.
5.
Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, et al: EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017; 71: 462–475.
6.
Singer S, Ziegler C, Schwalenberg T, et al: Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer 2013; 21: 1383–1393.
7.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466–465;discussion 475–467.
8.
Schmidt S, Frances A, Lorente Garin JA, et al: Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol 2015; 33: 19.e7–15.e15.
9.
Blazeby JM, Hall E, Aaronson NK, et al: Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 2014; 66: 1148–1156.
10.
Cody JD, Nabi G, Dublin N, et al: Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev 2012; 2:CD003306.
11.
Hautmann RE, Abol-Enein H, Davidsson T, et al: ICUD-EAU international consultation on bladder cancer 2012: urinary diversion. Eur Urol 2013; 63: 67–80.
12.
Dräger DL, Müller MM, Johnscher T, Kunz B, Sievert KD, Hakenberg OW: Psychosoziale aspekte von harnblasenkarzinompatienten. Onkologe 2018; 24: 64–68.
13.
Mehnert A, Müller D, Lehmann C, Koch U: Die deutsche version des NCCN distress-thermometers empirische prüfung eines screening-instruments zur erfassung psychosozialer belastung bei krebspatienten. Zeitschrift für Psychiatrie, Psychologie Psychother 2006; 54: 213–223.
14.
National Comprehensive Cancer Network: Distress management. Clinical practice guidelines. J Natl Compr Canc Netw 2003; 1: 344–374.
15.
Strittmatter G, Mawick R, Tilkorn M: -Entwicklung und klinischer einsatz von screening-instrumenten zur identifikation betreuungsbedürftiger tumorpatienten; in Bullinger M, Siegrist J, Ravens-Sieberer U (eds): Lebensqualitätsforschung aus Medizin-psychologischer und – soziologischer Perspektive. Jahrbuch der Medizinischen Psychologie. 2000, vol 18, pp 59–75.
16.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Psychoonkologische Diagnostik, Beratung und Behandlung Von Erwachsenen Krebspatienten, Leitlinienreport 1.0, 2014, AWMF, Registernummer: 032/051OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html.
17.
Kasparian NA: Psychological stress and melanoma: are we meeting our patients’ psychological needs? Clin Dermatol 2013; 31: 41–46.
18.
Yanez B, Bustillo NE, Antoni MH, Lechner SC, Dahn J, Kava B, et al: The importance of perceived stress management skills for patients with prostate cancer in active surveillance. J Behav Med 2015; 38: 214–222.
19.
Ficarra V, Righetti R, D’Amico A, Pilloni S, Balzarro M, Schiavone D, et al: General state of health and psychological well-being in patients after surgery for urological malignant neoplasms. Urol Int 2000; 65: 130–134.
20.
Henningsohn L, Wijkström H, Pedersen J, Ahlstrand C, Aus G, Bergmark K, et al: Time after surgery, symptoms and well-being in survivors of urinary bladder cancer. BJU Int 2003; 91: 325–330.
21.
Yang YL, Liu L, Li MY, Shi M, Wang L: Psychological disorders and psychosocial resources of patients with newly diagnosed bladder and kidney cancer: a cross-sectional study. PLoS One 2016; 11:e0155607.
22.
Palapattu GS, Haisfield-Wolfe ME, Walker JM, BrintzenhofeSzoc K, Trock B, Zabora J, Schoenberg M: Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol 2004; 172(5 pt 1): 1814–1817.
23.
Burge F, Kockelbergh R: Closing the gender gap: can we improve bladder cancer survival in women? – a systematic review of diagnosis, treatment and outcomes. Urol Int 2016; 97: 373–379
24.
Gacci M, Saleh O, Cai T, Gore JL, D’Elia C, Minervini A, Masieri L, Giannessi C, Lanciotti M, Varca V, Simonato A, Serni S, Carmignani G, Carini M: Quality of life in women undergoing urinary diversion for bladder cancer: results of a multicenter study among long-term disease-free survivors. Health Qual Life Outcomes 2013; 11: 43.
25.
Siracusano S, D'Elia C, Cerruto MA, Saleh O, Serni S, Gacci M, Ciciliato S, Simonato A, et al: Quality of life in patients with bladder cancer undergoing ileal conduit: a comparison of women versus men. In Vivo 2018; 32: 139–143.
26.
Siracusano S, Niero M, Lonardi C, Cerruto MA, Ciciliato S, Toffoli L, Visalli F, et al: Development of a questionnaire specifically for patients with Ileal Orthotopic Neobladder (IONB). Health Qual Life Outcomes 2014; 12: 135.
27.
EORTC Quality of life. Bladder Cancer: EORTC QLQ-NMIBC24, EORTC QLQ- BLM30. http://groups.eortc.be/qol/bladder-cancer-eortc-qlq-nmibc24-eortc-qlq-blm30.
28.
D’Elia C, Comploj E, Cerruto MA, Trenti E, Palermo SM, Melotti R, Artibani W, Pycha A: 90-Day mortality after radical cystectomy for bladder cancer: prognostic factors in a multicenter case series. Urol Int 2017; 98: 255–261.
29.
Heyes SM, Bond MJ, Harrington A, Belan I: The relative contributions of function, perceived psychological burden and partner support to cognitive distress in bladder cancer. Psychooncology 2016; 25: 1043–1049.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.